BioNTech SE (BNTX)
Bid | 95.27 |
Market Cap | 23.16B |
Revenue (ttm) | 2.74B |
Net Income (ttm) | -673.89M |
EPS (ttm) | -3.05 |
PE Ratio (ttm) | -31.64 |
Forward PE | -36.66 |
Analyst | Buy |
Ask | 97.26 |
Volume | 1,021,844 |
Avg. Volume (20D) | 861,408 |
Open | 93.70 |
Previous Close | 93.12 |
Day's Range | 92.11 - 97.08 |
52-Week Range | 76.53 - 131.49 |
Beta | 1.08 |
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for tripl...
Analyst Forecast
According to 16 analyst ratings, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $144, which is an increase of 49.21% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

3 weeks ago · seekingalpha.com
BioNTech's Pivot Into Oncology Still Makes It A Compelling InvestmentBioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. However, note that some regulatory and legal challenges, including a Moderna patent rul...